Overview

FOLFIRINOX + NIS793 in Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: - NIS793 - FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include - chemoradiation - surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Colin D. Weekes, M.D.
Collaborator:
Novartis
Treatments:
Camptothecin
Capecitabine
Fluorouracil
Folfirinox
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin